Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03649971 · ClinicalTrials.gov registry record · Phase 1
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT03649971 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 77 participants.
The verdict
NCT03649971, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
Interventions
- DRUG Placebo
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2022-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03649971
The ClinicalTrials.gov registry entry for NCT03649971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03649971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03649971 about?
NCT03649971 is a clinical study titled "A Study of Guselkumab in Participants With Familial Adenomatous Polyposis". The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
What is the current status of trial NCT03649971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2018-11-19. Estimated completion is 2022-03-23.
What interventions are being tested in trial NCT03649971?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT03649971?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.